Overview

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status:
Recruiting

Trial end date:
2023-05-31

Target enrollment:

Participant gender:

Summary

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Phase:

Phase 2

Details

Lead Sponsor:

Xynomic Pharmaceuticals, Inc.

Treatments:

Abexinostat